1/22/2020 7:22:12 AM
Axsome Completes Patient Randomization In STRIDE-1 Phase 3 Trial Of AXS-05
12/30/2019 6:16:08 AM
Axsome Therapeutics Announces AXS-07 Meets Co-Primary And Key Secondary Endpoints In MOMENTUM Phase 3 Migraine Trial
12/19/2019 7:13:39 AM
Axsome Therapeutics Prices Public Offering Of 2 Mln Shares At $87/Shr
12/17/2019 7:11:43 AM
Axsome Therapeutics Says Elected For Addition To NASDAQ Biotechnology Index
12/16/2019 6:03:54 AM
Axsome Therapeutics Says AXS-05 Met Primary Endpoint In GEMINI Phase 3 Trial
12/3/2019 6:10:25 AM
Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint In CONCERT Phase 2 Trial In Narcolepsy
11/21/2019 7:22:20 AM
Axsome Therapeutics To Host Investor R&D Call Focusing On AXS-07
10/21/2019 7:08:44 AM
Axsome Therapeutics Completes Patient Enrollment In CONCERT Study
10/16/2019 7:07:17 AM
Axsome Therapeutics Completes Patient Enrollment In GEMINI Phase 3 Trial Of AXS-05 In Major Depressive Disorder
10/2/2019 7:10:56 AM
Axsome Therapeutics To Provide Update On Continued Progress At 2019 Cantor Global Healthcare Conference
9/5/2019 7:11:07 AM
Axsome To Present Positive Results From Phase 1 Pharmacokinetic Trial Of AXS-07
6/7/2019 7:05:18 AM
Axsome Therapeutics Provides Update On Continued Progress At Annual Stockholders’ Meeting